Sanofi and Regeneron announce positive Phase 3 monotherapy study results
Sanofi and Regeneron Pharmaceuticals announced that the Phase 3 study of monotherapies set to demonstrate the superiority of sarilumab to adalimumab when treating active rheumatoid arthritis (RA) has met its primary goal. Read More »